On 16th, October 2024, Hasten Biopharmaceutical Co., Ltd. (hereinafter as Hasten) announced that a new network META article of azilsartan medoxomil (AZL-M) titled "A systematic literature review and network meta-analysis of azilsartan medoxomil compared to other anti-hypertensives efficacy in lowering blood pressure amongst mild to moderate hypertensive patients" had been published in the internationally renowned journal Advances in Therapy.

   

On Feb. 27th, 2024, Hasten Biopharmaceutical Limited Co., Ltd. (hereinafter as Hasten Biopharma) announced that the clinical trial application (IND) for Lerodalcibep, a novel third-generation PCSK9 inhibitor, has been accepted by the Center for Drug Evaluation(CDE) of the National Medical Products Administration (NMPA) for the treatment of patients with hypercholesterolemia and further reduction their low-density lipoprotein cholesterol (LDL-C) levels.

“Edarbi® NRDL Launch Conference” was held in Beijing, Shanghai and Guangzhou on March 25 of 2023. More than 280 top domestic experts in the field of cardiovascular disease and management team from Hasten Biopharma attended the event, focusing on the review of the history for hypertension prevention and treatment in China during the past 30 years and discussion on a new chapter of blood pressure lowering and standardization.

March 1st  2023, Professor Wang Jiguang from the Department of Hypertension at Ruijin Hospital，issued the first prescription for Azilsartan Medoxomil Potassium Tablets (Edarbi®) after the official implementation of the new version of National Reimbursement Drug List (NRDL). The Azilsartan Medoxomil Potassium Tablets, a powerful antihypertensive drug of the angiotensin receptor blocker (ARB) class, is mainly used for the treatment of adults with essential hypertension. After entering the new edition of the NRDL, its price reduction of nearly 70% has further relieved the burden of patients and improved the accessibility of antihypertensive drugs.

(August 19, 2022) In order to further help improve the rate for awareness of hypertension management in the population, the "Easy“ to Meet the Standard - 2022 Cardiovascular Disease Blood Pressure Standard Achievement Program, initiated by the Suzhou Industrial Park Institute of Cardiovascular Health and supported by Hasten Biopharma. The kick-off meeting of the management project was successfully held in the afternoon of August 19, 2022 in Hefei, Anhui Province, China, in the session of the International Conference on Cardiovascular Diseases of Confucianism. The conference focused on optimal management of hypertension and its related hot issues.